Skip navigation
Watchlist Sponsored By :


Current DateTime: 07:54:37 26 Nov 2009
LinksList Documentid: 24355697
  • Runway Angels

      The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.

  • Smartphone Guide

      Here's a need-to-know guide to nine devices, based on features, price, network and platform.

  • Wines for the Holidays

      Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES


Current DateTime: 07:54:37 26 Nov 2009
LinksList Documentid: 33793611
  • How Well Do You Know Your Bird?

      Let's talk turkey. Test your turkey knowledge and perhaps pick up a bit of trivia to trot out at your holiday meal.

  • A Healthier & Wealthier You

      Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.

  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?


Current DateTime: 07:54:37 26 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
GlaxoSmithKline Posts 16% Rise in Full-Year Profit
By: CNBC.com | 08 Feb 2007 | 08:08 AM ET
Text Size

GlaxoSmithKline, [GSK  Loading...      ()   ] Europe's biggest drug maker, reported a 16% rise in annual profit Thursday, in line with expectations of analysts polled by Reuters. But the company said 2007 growth would slow as it awaits pipeline renewal.

Fourth-quarter profit before tax was $2.2 billion, up from $2.08 billion in the same three months ending December in 2005.

Sales in the fourth-quarter rose to $7.79 billion from $7.66 billion, helped by strong U.S. demand.

For the coming year, GSK forecast EPS growth in constant exchange rate terms of between 8% to 10% -- better than the low single-digit level some analysts had expected.

GSK said that it plans launch 5 major new pharmaceutical products in 2007:Tykerb, which is a breast cancer drug; Allermist/Avamys, a allergic rhinitis treatment; Coreg, for treating heart conditions and Trexima for migraines. The company also, said that it expects to file for U.S. approval for cervical cancer vaccine Cervarix in April.

Competition from generic drug makers will increase for major pharmaceuticals in 2007, and GSK is no exception with both its anti-nausea drug Zofran and anti-depressant Wellbutrin XL set to face new rivals.

The company's shares rose more than 1% in London in reaction to the results.

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
  • Ever wished your cab driver would stop nattering and just get to where you're going? Well that moment is near(er).
  • Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
  • Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
  • More shoppers than ever plan to comparison-shop this season. Who will benefit?
  • It may be the most unusual guide to business you'll read.
ADD COMMENTS
Remaining characters


Current DateTime: 01:44:15 26 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:03:48 26 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:07:49 26 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:02:06 26 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters